<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37190840</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1002-1892</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery</Title><ISOAbbreviation>Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Analysis of incidence and clinical characteristics of osteonecrosis of femoral head in patients with systemic lupus erythematosus treated with glucocorticoid: A descriptive study based on a prospective cohort].</ArticleTitle><Pagination><StartPage>605</StartPage><EndPage>614</EndPage><MedlinePgn>605-614</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7507/1002-1892.202302026</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To describe the disease characteristics of osteonecrosis of the femoral head (ONFH) in patients with systemic lupus erythematosus (SLE) who experiencing prolonged glucocorticoid (GC) exposure.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Between January 2016 and June 2019, 449 SLE patients meeting the criteria were recruited from multiple centers. Hip MRI examinations were performed during screening and regular follow-up to determine the occurrence of ONFH. The cohort was divided into ONFH and non-ONFH groups, and the differences in demographic baseline characteristics, general clinical characteristics, GC medication information, combined medication, and hip clinical features were compared and comprehensively described.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The age at SLE diagnosis was 29.8 (23.2, 40.9) years, with 93.1% (418 cases) being female. The duration of GC exposure was 5.3 (2.0, 10.5) years, and the cumulative incidence of SLE-ONFH was 9.1%. Significant differences ( <i>P</i>&lt;0.05) between ONFH and non-ONFH groups were observed in the following clinical characteristics: &#x2460; Demographic baseline characteristics: ONFH group had a higher proportion of patients with body mass index (BMI)&lt;20 kg/m <sup>2</sup> compared to non-ONFH group. &#x2461; General clinical characteristics: ONFH group showed a higher proportion of patients with cutaneous and renal manifestations, positive antiphospholipid antibodies (aPLs) and anticardiolipin antibodies, severe SLE patients [baseline SLE Disease Activity Index 2000 (SLEDAI-2K) score &#x2265;15], and secondary hypertension. Fasting blood glucose in ONFH group was also higher. &#x2462; GC medication information: ONFH group had higher initial intravenous GC exposure rates, duration, cumulative doses, higher cumulative GC doses in the first month and the first 3 months, higher average daily doses in the first 3 months, and higher proportions of average daily doses &#x2265;15.0 mg/d and &#x2265;30.0 mg/d, as well as higher full-course average daily doses and proportion of full-course daily doses &#x2265;30.0 mg/d compared to non-ONFH group. &#x2463; Combined medications: ONFH group had a significantly higher rate of antiplatelet drug use than non-ONFH group. &#x2464; Hip clinical features: ONFH group had a higher proportion of hip discomfort or pain and a higher incidence of hip joint effusion before MRI screening than non-ONFH group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The incidence of ONFH after GC exposure in China's SLE population remains high (9.1%), with short-term (first 3 months), medium-to-high dose (average daily dose &#x2265;15 mg/d) GC being closely associated with ONFH. Severe SLE, low BMI, certain clinical phenotypes, positive aPLs, and secondary hypertension may also be related to ONFH.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shengbao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Qianying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Changqing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi</MedlineTA><NlmUniqueID>9425194</NlmUniqueID><ISSNLinking>1002-1892</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005270" MajorTopicYN="N">Femur Head</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005271" MajorTopicYN="Y">Femur Head Necrosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText Label="&#x76ee;&#x7684;" NlmCategory="UNASSIGNED">&#x63cf;&#x8ff0;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#xff08;systemic lupus erythematosus&#xff0c;SLE&#xff09;&#x60a3;&#x8005;&#x957f;&#x671f;&#x7cd6;&#x76ae;&#x8d28;&#x6fc0;&#x7d20;&#xff08;glucocorticoid&#xff0c;GC&#xff09;&#x66b4;&#x9732;&#x53d1;&#x751f;&#x80a1;&#x9aa8;&#x5934;&#x574f;&#x6b7b;&#xff08;osteonecrosis of the femoral head&#xff0c;ONFH&#xff09;&#x7684;&#x60a3;&#x75c5;&#x7279;&#x5f81;&#x3002;.</AbstractText><AbstractText Label="&#x65b9;&#x6cd5;" NlmCategory="UNASSIGNED">2016&#x5e74;1&#x6708;&#x2014;2019&#x5e74;6&#x6708;&#xff0c;&#x7531;&#x591a;&#x4e2d;&#x5fc3;&#x62db;&#x52df;&#x7b26;&#x5408;&#x6807;&#x51c6;&#x7684;449&#x4f8b;SLE&#x60a3;&#x8005;&#x4f5c;&#x4e3a;&#x7814;&#x7a76;&#x5bf9;&#x8c61;&#xff0c;&#x5206;&#x522b;&#x5728;&#x7b5b;&#x9009;&#x5165;&#x7ec4;&#x53ca;&#x5b9a;&#x671f;&#x968f;&#x8bbf;&#x89c2;&#x5bdf;&#x65f6;&#x8fdb;&#x884c;&#x9acb;&#x5173;&#x8282;MRI&#x68c0;&#x67e5;&#xff0c;&#x5224;&#x65ad;&#x662f;&#x5426;&#x51fa;&#x73b0;ONFH&#x3002;&#x5c06;&#x961f;&#x5217;&#x4eba;&#x7fa4;&#x5206;&#x4e3a;ONFH&#x7ec4;&#x548c;&#x975e;ONFH&#x7ec4;&#xff0c;&#x6bd4;&#x8f83;&#x4e24;&#x7ec4;&#x4e4b;&#x95f4;&#x4eba;&#x53e3;&#x5b66;&#x57fa;&#x7ebf;&#x7279;&#x5f81;&#x3001;&#x4e00;&#x822c;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#x3001;GC&#x7528;&#x836f;&#x4fe1;&#x606f;&#x3001;&#x5408;&#x5e76;&#x7528;&#x836f;&#x60c5;&#x51b5;&#x53ca;&#x9acb;&#x90e8;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#x7684;&#x5dee;&#x5f02;&#xff0c;&#x4f5c;&#x7efc;&#x5408;&#x6027;&#x63cf;&#x8ff0;&#x3002;.</AbstractText><AbstractText Label="&#x7ed3;&#x679c;" NlmCategory="UNASSIGNED">&#x60a3;&#x8005;&#x786e;&#x8bca;SLE&#x65f6;&#x5e74;&#x9f84;&#x4e3a;29.8&#xff08;23.2&#xff0c;40.9&#xff09;&#x5c81;&#xff0c;&#x5973;&#x6027;&#x5360;93.1%&#xff08;418&#x4f8b;&#xff09;&#xff0c;GC&#x66b4;&#x9732;&#x65f6;&#x95f4;&#x4e3a;5.3&#xff08;2.0&#xff0c;10.5&#xff09;&#x5e74;&#xff0c;SLE-ONFH&#x7d2f;&#x8ba1;&#x65b0;&#x53d1;&#x75c5;&#x7387;&#x4e3a;9.1%&#x3002;ONFH&#x548c;&#x975e;ONFH&#x4e24;&#x7ec4;&#x4ee5;&#x4e0b;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#x5dee;&#x5f02;&#x6709;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;&#xff08; <i>P</i>&lt;0.05&#xff09;&#xff1a;&#x2460; &#x4eba;&#x53e3;&#x5b66;&#x57fa;&#x7ebf;&#x7279;&#x5f81;&#xff1a;ONFH&#x7ec4;&#x8eab;&#x4f53;&#x8d28;&#x91cf;&#x6307;&#x6570;&#xff08;body mass index&#xff0c;BMI&#xff09;&lt;20 kg/m <sup>2</sup>&#x60a3;&#x8005;&#x6bd4;&#x4f8b;&#x5927;&#x4e8e;&#x975e;ONFH&#x7ec4;&#x3002;&#x2461; &#x4e00;&#x822c;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#xff1a;ONFH&#x7ec4;&#x76ae;&#x80a4;&#x9ecf;&#x819c;&#x578b;&#x548c;&#x80be;&#x578b;&#x60a3;&#x8005;&#x6bd4;&#x4f8b;&#xff0c;&#x7a7a;&#x8179;&#x8840;&#x7cd6;&#x3001;&#x4efb;&#x4e00;&#x6297;&#x78f7;&#x8102;&#x6297;&#x4f53;&#xff08;antiphospholipid antibodies&#xff0c;aPLs&#xff09;&#x9633;&#x6027;&#x53ca;&#x6297;&#x5fc3;&#x78f7;&#x8102;&#x6297;&#x4f53;&#x9633;&#x6027;&#x6bd4;&#x4f8b;&#xff0c;&#x91cd;&#x75c7;SLE&#x60a3;&#x8005; &#xff3b;&#x57fa;&#x7ebf;SLE&#x6d3b;&#x52a8;&#x6307;&#x6570;2000&#xff08;SLEDAI-2K&#xff09;&#x8bc4;&#x5206;&#x2265;15&#x5206;&#xff3d;&#x6bd4;&#x4f8b;&#xff0c;&#x4ee5;&#x53ca;&#x7ee7;&#x53d1;&#x52a8;&#x8109;&#x6027;&#x9ad8;&#x8840;&#x538b;&#x6bd4;&#x4f8b;&#x5747;&#x660e;&#x663e;&#x9ad8;&#x4e8e;&#x975e;ONFH&#x7ec4;&#x3002;&#x2462; GC&#x7528;&#x836f;&#x4fe1;&#x606f;&#xff1a;ONFH&#x7ec4;&#x8f83;&#x975e;ONFH&#x7ec4;&#x6709;&#x66f4;&#x9ad8;&#x7684;&#x521d;&#x59cb;&#x9636;&#x6bb5;&#x9759;&#x8109;GC&#x66b4;&#x9732;&#x6bd4;&#x4f8b;&#x3001;&#x6301;&#x7eed;&#x65f6;&#x95f4;&#x3001;&#x7d2f;&#x8ba1;&#x5242;&#x91cf;&#xff0c;&#x66f4;&#x9ad8;&#x7684;&#x9996;&#x6708;&#x53ca;&#x524d;3&#x4e2a;&#x6708;GC&#x7d2f;&#x8ba1;&#x5242;&#x91cf;&#x3001;&#x524d;3&#x4e2a;&#x6708;&#x65e5;&#x5747;&#x5242;&#x91cf;&#x53ca;&#x524d;3&#x4e2a;&#x6708;&#x65e5;&#x5747;&#x5242;&#x91cf;&#x2265;15.0 mg/d&#x3001;&#x2265;30.0 mg/d&#x6bd4;&#x4f8b;&#xff0c;&#x4ee5;&#x53ca;&#x66f4;&#x9ad8;&#x7684;&#x5168;&#x7a0b;&#x65e5;&#x5747;&#x5242;&#x91cf;&#x548c;&#x5168;&#x7a0b;&#x65e5;&#x5747;&#x5242;&#x91cf;&#x2265;30.0 mg/d&#x6bd4;&#x4f8b;&#x3002;&#x2463; &#x5408;&#x5e76;&#x7528;&#x836f;&#x60c5;&#x51b5;&#xff1a;ONFH&#x7ec4;&#x6297;&#x8840;&#x5c0f;&#x677f;&#x836f;&#x5e94;&#x7528;&#x7387;&#x663e;&#x8457;&#x9ad8;&#x4e8e;&#x975e;ONFH&#x7ec4;&#x3002;&#x2464; &#x9acb;&#x90e8;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#xff1a;ONFH&#x7ec4;MRI&#x7b5b;&#x67e5;&#x524d;&#x5df2;&#x51fa;&#x73b0;&#x9acb;&#x90e8;&#x4e0d;&#x9002;&#x6216;&#x75bc;&#x75db;&#x53d1;&#x751f;&#x6bd4;&#x4f8b;&#x3001;&#x9acb;&#x5173;&#x8282;&#x8154;&#x79ef;&#x6db2;&#x53d1;&#x751f;&#x7387;&#x5747;&#x660e;&#x663e;&#x9ad8;&#x4e8e;&#x975e;ONFH&#x7ec4;&#x3002;.</AbstractText><AbstractText Label="&#x7ed3;&#x8bba;" NlmCategory="UNASSIGNED">&#x76ee;&#x524d;&#x56fd;&#x5185;SLE&#x4eba;&#x7fa4;GC&#x66b4;&#x9732;&#x540e;ONFH&#x53d1;&#x751f;&#x7387;&#x4ecd;&#x8f83;&#x9ad8;&#xff08;9.1%&#xff09;&#xff0c;&#x5176;&#x4e2d;&#x77ed;&#x65f6;&#x95f4;&#xff08;&#x524d;3&#x4e2a;&#x6708;&#xff09;&#x4e2d;&#x9ad8;&#x5242;&#x91cf;&#xff08;&#x65e5;&#x5747;&#x5242;&#x91cf;&#x2265;15 mg/d&#xff09;GC&#x4e0e;ONFH&#x5bc6;&#x5207;&#x5173;&#x8054;&#xff0c;&#x800c;&#x91cd;&#x75c7;SLE&#x3001;&#x4f4e;BMI&#x3001;&#x90e8;&#x5206;&#x4e34;&#x5e8a;&#x8868;&#x578b;&#x3001;aPLs&#x9633;&#x6027;&#x53ca;&#x7ee7;&#x53d1;&#x52a8;&#x8109;&#x6027;&#x9ad8;&#x8840;&#x538b;&#x7b49;&#x56e0;&#x7d20;&#x53ef;&#x80fd;&#x4e0e;ONFH&#x76f8;&#x5173;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">clinical characteristics</Keyword><Keyword MajorTopicYN="N">glucocorticoid</Keyword><Keyword MajorTopicYN="N">osteonecrosis of the femoral head</Keyword></KeywordList><CoiStatement>&#x5229;&#x76ca;&#x51b2;&#x7a81;&#x3000;&#x5728;&#x8bfe;&#x9898;&#x7814;&#x7a76;&#x548c;&#x6587;&#x7ae0;&#x64b0;&#x5199;&#x8fc7;&#x7a0b;&#x4e2d;&#x4e0d;&#x5b58;&#x5728;&#x5229;&#x76ca;&#x51b2;&#x7a81;&#xff1b;&#x57fa;&#x91d1;&#x7ecf;&#x8d39;&#x652f;&#x6301;&#x6ca1;&#x6709;&#x5f71;&#x54cd;&#x6587;&#x7ae0;&#x89c2;&#x70b9;&#x548c;&#x5bf9;&#x7814;&#x7a76;&#x6570;&#x636e;&#x5ba2;&#x89c2;&#x7ed3;&#x679c;&#x7684;&#x7edf;&#x8ba1;&#x5206;&#x6790;&#x53ca;&#x5176;&#x62a5;&#x9053;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>3</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37190840</ArticleId><ArticleId IdType="pmc">PMC10196977</ArticleId><ArticleId IdType="doi">10.7507/1002-1892.202302026</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Powell C, Chang C, Gershwin ME Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis. Clin Rev Allergy Immunol. 2011;41(1):102&#x2013;113. doi: 10.1007/s12016-010-8217-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-010-8217-z</ArticleId><ArticleId IdType="pubmed">21161435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Yin J, Ding H, et al Vitamin K2 ameliorates damage of blood vessels by glucocorticoid: a potential mechanism for its protective effects in glucocorticoid-induced osteonecrosis of the femoral head in a rat model. Int J Biol Sci. 2016;12(7):776&#x2013;785. doi: 10.7150/ijbs.15248.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.15248</ArticleId><ArticleId IdType="pmc">PMC4910597</ArticleId><ArticleId IdType="pubmed">27313492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerachian MA, S&#xe9;guin C, Harvey EJ Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 2009;114(3-5):121&#x2013;128. doi: 10.1016/j.jsbmb.2009.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2009.02.007</ArticleId><ArticleId IdType="pmc">PMC7126235</ArticleId><ArticleId IdType="pubmed">19429441</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x90d1;&#x671d;&#x6656;, &#x8d75;&#x5360;&#x6b63;, &#x5218;&#x7ae0;&#x9501; &#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x5e76;&#x53d1;&#x80a1;&#x9aa8;&#x5934;&#x574f;&#x6b7b;&#x76f8;&#x5173;&#x56e0;&#x7d20;&#x5206;&#x6790;. &#x4e2d;&#x56fd;&#x8bef;&#x8bca;&#x5b66;&#x6742;&#x5fd7;. 2006;6(17):3311&#x2013;3312. doi: 10.3969/j.issn.1009-6647.2006.17.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1009-6647.2006.17.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Garcia M, Espinosa G, et al First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med. 2016;3(1):e000153. doi: 10.1136/lupus-2016-000153. doi: 10.1136/lupus-2016-000153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000153</ArticleId><ArticleId IdType="pmc">PMC4985804</ArticleId><ArticleId IdType="pubmed">27547439</ArticleId></ArticleIdList></Reference><Reference><Citation>Safiri S, Ayubi E Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus: methodological issues. Lupus. 2018;27(1):174. doi: 10.1177/0961203317734920. doi: 10.1177/0961203317734920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317734920</ArticleId><ArticleId IdType="pubmed">28992801</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrod L Glucocorticoid therapy. Medicine (Baltimore) 1976;55(1):39&#x2013;65. doi: 10.1097/00005792-197601000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-197601000-00003</ArticleId><ArticleId IdType="pubmed">173974</ArticleId></ArticleIdList></Reference><Reference><Citation>Global BMI Mortality Collaboration, Angelantonio ED, Bhupathiraju S, et al Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776&#x2013;786. doi: 10.1016/S0140-6736(16)30175-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30175-1</ArticleId><ArticleId IdType="pmc">PMC4995441</ArticleId><ArticleId IdType="pubmed">27423262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevskaya T, Gamble MP, Pope JE A meta-analysis of avascular necrosis in systemic lupus erythematosus: Prevalence and risk factors. Clin Exp Rheumatol. 2017;35(4):700&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">28240590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunyakham W, Foocharoen C, Mahakkanukrauh A, et al Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Pacific J Allergy Immunol. 2012;30(2):152&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">22830295</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo YB, Sung YK, Shim JS, et al Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study. Rheumatol Int. 2015;35(5):879&#x2013;886. doi: 10.1007/s00296-014-3147-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-014-3147-3</ArticleId><ArticleId IdType="pubmed">25300729</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto M A prospective study of steroid-induced osteonecrosis by MRI screening. Ni hon Seikeigeka Gakkai Zasshi. 1994;68(5):367&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">8051464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mont MA, Zywiel MG, Marker DR, et al The natural history of untreated asymptomatic osteonecrosis of the femoral head: A systematic literature review. J Bone Joint Surg (Am) 2010;92(12):2165&#x2013;2170. doi: 10.2106/JBJS.I.00575.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.I.00575</ArticleId><ArticleId IdType="pubmed">20844158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagasawa K, Tada Y, Koarada S, et al Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus. 2005;14(5):385&#x2013;390. doi: 10.1191/0961203305lu2103oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203305lu2103oa</ArticleId><ArticleId IdType="pubmed">15934439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte A, Danza A, Ruiz-Irastorza G Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2018;30(5):482&#x2013;489. doi: 10.1097/BOR.0000000000000527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000527</ArticleId><ArticleId IdType="pubmed">29870497</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: An observational study. Arthritis Care Res (Hoboken) 2018;70(4):582&#x2013;591. doi: 10.1002/acr.23322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23322</ArticleId><ArticleId IdType="pubmed">28704598</ArticleId></ArticleIdList></Reference><Reference><Citation>Massardo L, Jacobelli S, Leissner M, et al High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus. 1992;1(6):401&#x2013;405. doi: 10.1177/096120339200100610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339200100610</ArticleId><ArticleId IdType="pubmed">1304409</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit F, da Silva JA, Boers M, et al Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718&#x2013;722. doi: 10.1136/ard.61.8.718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.61.8.718</ArticleId><ArticleId IdType="pmc">PMC1754188</ArticleId><ArticleId IdType="pubmed">12117678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoli AM, Fern&#xe1;ndez M, Calvo-Al&#xe9;n J, et al Systemic lupus erythematosus in a multiethnic U. S. cohort (LUMINA) XXXI:factors associated with patients being lost to follow-up. Lupus. 2006;15(1):19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16482741</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad R, Ibanez D, Gladman D, et al The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16(3):157&#x2013;162. doi: 10.1177/0961203306075771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306075771</ArticleId><ArticleId IdType="pubmed">17432099</ArticleId></ArticleIdList></Reference><Reference><Citation>Felson DT, Anderson JJ Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. 1987;1(8538):902&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">2882300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanaka H, Motomura G, Ikemura S, et al Differences in magnetic resonance findings between symptomatic and asymptomatic pre-collapse osteonecrosis of the femoral head. Eur J Radiol. 2019;112:1&#x2013;6. doi: 10.1016/j.ejrad.2019.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2019.01.002</ArticleId><ArticleId IdType="pubmed">30777197</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Yi H, Zhang Z, et al Association of hip joint effusion volume with early osteonecrosis of the femoral head. Hip Int. 2012;22(2):179&#x2013;183. doi: 10.5301/HIP.2012.9237.</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/HIP.2012.9237</ArticleId><ArticleId IdType="pubmed">22547378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell DG, Rao V, Dalinka M, et al MRI of joint fluid in the normal and ischemic hip. AJR Am J Roentgenol. 1986;146(6):1215&#x2013;1218. doi: 10.2214/ajr.146.6.1215.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/ajr.146.6.1215</ArticleId><ArticleId IdType="pubmed">3486565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, et al Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Ueowitz MB Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Eudy AM, Siega-Riz AM, Engel SM, et al Preconceptional cardiovascular health and pregnancy outcomes in women with eystemic Lupus Erythematosus. J Rheumatol. 2019;46(1):70&#x2013;77. doi: 10.3899/jrheum.171066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.171066</ArticleId><ArticleId IdType="pmc">PMC6314889</ArticleId><ArticleId IdType="pubmed">30008449</ArticleId></ArticleIdList></Reference><Reference><Citation>Perna S, Giacosa A, Bonitta G, et al Effects of hazelnut consumption on blood lipids and body weight: A systematic review and bayesian meta-analysis. Nutrients. 2016;8(12):747. doi: 10.3390/nu8120747. doi: 10.3390/nu8120747.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu8120747</ArticleId><ArticleId IdType="pmc">PMC5188407</ArticleId><ArticleId IdType="pubmed">27897978</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XC, Weng J, Chen XQ, et al Relationships among magnetic resonance imaging, histological findings, and IGF-I in steroid-induced osteonecrosis of the femoral head in rabbits. J Zhejiang Univ Sci B. 2008;9(9):739&#x2013;746. doi: 10.1631/jzus.B0820127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.B0820127</ArticleId><ArticleId IdType="pmc">PMC2528890</ArticleId><ArticleId IdType="pubmed">18837481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitajima M, Shigematsu M, Ogawa K, et al Effects of glucocorticoid on adipocyte size in human bone marrow. Med Mol Morphol. 2007;40(3):150&#x2013;156. doi: 10.1007/s00795-007-0367-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00795-007-0367-6</ArticleId><ArticleId IdType="pubmed">17874047</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss JH, Misselevich I Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol. 2003;40(4):345&#x2013;354. doi: 10.1354/vp.40-4-345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1354/vp.40-4-345</ArticleId><ArticleId IdType="pubmed">12824505</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengde K, Fuxing P, Bin S, et al Lovastatin inhibits adipogenesis and prevents osteonecrosis in steroid-treated rabbits. Joint Bone Spine. 2008;75(6):696&#x2013;701. doi: 10.1016/j.jbspin.2007.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2007.12.008</ArticleId><ArticleId IdType="pubmed">18620886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Carrio J, Mart&#xed;nez-Zapico A, Cabezas-Rodr&#xed;guez I, et al Clinical and subclinical cardiovascular disease in female SLE patients: Interplay between body mass index and bone mineral density. Nutr Metab Cardiovasc Dis. 2019;29(2):135&#x2013;143. doi: 10.1016/j.numecd.2018.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2018.09.007</ArticleId><ArticleId IdType="pubmed">30559042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung JY, Kim HA, Lee HY, et al Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4 year follow-up study. Int J Rheum Dis. 2019;22(8):1410&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pubmed">31050219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda T, Tanabe N, Wakamatsu A, et al High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Rheumatol. 2015;34(12):2071&#x2013;2077. doi: 10.1007/s10067-015-3075-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-3075-y</ArticleId><ArticleId IdType="pubmed">26384821</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN &#x2018;Not only. . but also&#x2019;: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005;44(12):1492&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234277</ArticleId></ArticleIdList></Reference><Reference><Citation>Liverani E, Banerjee S, Roberts W, et al Prednisolone exerts exquisite inhibitory properties on platelet functins. Biochem Pharmacol. 2012;83(10):1364&#x2013;1373. doi: 10.1016/j.bcp.2012.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2012.02.006</ArticleId><ArticleId IdType="pmc">PMC3320711</ArticleId><ArticleId IdType="pubmed">22366284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Lv J, Jin L Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head. J Int Med Res. 2018;46(6):2141&#x2013;2148. doi: 10.1177/0300060517700299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060517700299</ArticleId><ArticleId IdType="pmc">PMC6023042</ArticleId><ArticleId IdType="pubmed">28459353</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawata K, Nakamura J, Ikeda K, et al Transitional changes in the incidence of osteonecrosis in systemic lupus erythematosus patients: focus on immunosuppressant agents and glucocorticoids. Rheumatology (Oxford) 2018;57(5):844&#x2013;849. doi: 10.1093/rheumatology/key009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key009</ArticleId><ArticleId IdType="pubmed">29462407</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagasawa K, Ishii Y, Mayumi T, et al Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis. 1989;48(8):672&#x2013;676. doi: 10.1136/ard.48.8.672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.48.8.672</ArticleId><ArticleId IdType="pmc">PMC1003845</ArticleId><ArticleId IdType="pubmed">2506841</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo-Al&#xe9;n J, McGwin G, Toloza S, et al Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients:results of a nested matched case-control study. Ann Rheum Dis. 2006;65(6):785&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1798170</ArticleId><ArticleId IdType="pubmed">16269429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Lin HC Increased risk for coronary heart disease after avascular necrosis of femoral head: A 3-year follow-up study. Am Heart J. 2010;159(5):803&#x2013;808. doi: 10.1016/j.ahj.2010.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2010.02.020</ArticleId><ArticleId IdType="pubmed">20435189</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Jansen-Chaparro S, Saigi I, et al Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6(1):9&#x2013;20. doi: 10.1111/1753-0407.12090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.12090</ArticleId><ArticleId IdType="pubmed">24103089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsuno I, Sugiyama T Glucocorticoid-induced diabetes mellitus is a risk for vertebral fracture during glucocorticoid treatment. Diabetes Res Clin Pract. 2011;93(1):e18&#x2013;e20. doi: 10.1016/j.diabres.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2011.03.005</ArticleId><ArticleId IdType="pubmed">21440321</ArticleId></ArticleIdList></Reference><Reference><Citation>Amengual O, Atsumi T Antiphospholipid syndrome, &#x201c;the best prophet of the future&#x201d;. Mod Rheumatol. 2018;28(3):409&#x2013;416. doi: 10.1080/14397595.2018.1435988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1435988</ArticleId><ArticleId IdType="pubmed">29385876</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen NJ, Schleich MA, Karp DR Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43(2):264&#x2013;272. doi: 10.1016/j.semarthrit.2013.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2013.01.001</ArticleId><ArticleId IdType="pubmed">23481418</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Sanna G, Khamashta MA, et al The estimated frequency of antiphospholipid antibodies in young adults with cerebro-vascular events: a systematic review. Ann Rheum Dis. 2015;74(11):2028&#x2013;2033. doi: 10.1136/annrheumdis-2014-205663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205663</ArticleId><ArticleId IdType="pubmed">24942381</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Rheinschmidt M, Whiting-OKeefe Q, et al The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med. 1987;106(4):524&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">3103510</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh JA, Sayed ME, Salah N, et al Predictors of avascular necrosis of the hip in Emiratis patients with systemic lupus erythematosus. Egypt J Immunol. 2010;17(1):29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22053607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponticelli C, Moroni G Hydroxychloroquine in systemic lupus erythematosus (SLE) Expert Opin Drug Saf. 2017;16(3):411&#x2013;419. doi: 10.1080/14740338.2017.1269168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2017.1269168</ArticleId><ArticleId IdType="pubmed">27927040</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011;13(1):77&#x2013;80. doi: 10.1007/s11926-010-0141-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-010-0141-y</ArticleId><ArticleId IdType="pubmed">20978875</ArticleId></ArticleIdList></Reference><Reference><Citation>Broder A, Putterman C Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40(1):30&#x2013;33. doi: 10.3899/jrheum.120157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.120157</ArticleId><ArticleId IdType="pmc">PMC3768146</ArticleId><ArticleId IdType="pubmed">22859353</ArticleId></ArticleIdList></Reference><Reference><Citation>Takao M, Sakai T, Nishii T, et al Incidence and predictors of osteonecrosis among cyclosporin- or tacrolimus-treated renal allograft recipients. Rheumatol Int. 2011;31(2):165&#x2013;170. doi: 10.1007/s00296-009-1241-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-009-1241-8</ArticleId><ArticleId IdType="pubmed">19862528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC Updating the American college of heumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, et al Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon HH, Bang SY, Won S, et al Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus. Lupus. 2018;27(10):1644&#x2013;1651. doi: 10.1177/0961203318784648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318784648</ArticleId><ArticleId IdType="pubmed">29950160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, et al Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28(4):761&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">11327247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozen L, Wallace DJ Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. Am J Orthop (Belle Mead NJ) 1998;27(5):352&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">9604106</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x90ed;&#x96e8;&#x51e1;, &#x5b59;&#x51cc;&#x4e91;, &#x90b9;&#x8000;&#x7ea2;, &#x7b49; 1958&#x4f8b;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x4f4f;&#x9662;&#x60a3;&#x8005;&#x9996;&#x53d1;&#x8868;&#x73b0;&#x548c;&#x8d77;&#x75c5;&#x7279;&#x70b9;&#x7684;&#x56de;&#x987e;&#x5206;&#x6790;. &#x4e2d;&#x534e;&#x98ce;&#x6e7f;&#x75c5;&#x5b66;&#x6742;&#x5fd7;. 2011;15(2):105&#x2013;107. doi: 10.3760/cma.j.issn.1007-7480.2011.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1007-7480.2011.02.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Li M, Zhao J, et al Chinese SLE Treatment and Research Group (CSTAR) registry: &#x2167;. Influence of socioeconomic and geographical variables on disease phenotype and activity in Chinese patients with SLE. Int J Rheum Dis. 2018;21(3):716&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">28296238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Lau CS, Wong RW Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol. 1998;37(8):895&#x2013;900. doi: 10.1093/rheumatology/37.8.895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/37.8.895</ArticleId><ArticleId IdType="pubmed">9734682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>